Recombinant vaccinia virus GLV-1h68 is a promising oncolytic vector in the treatment of cholangiocarcinoma

Amudhan Pugalenthi, Kelly Mojica, Justin W. Ady, Clark Johnsen, Damon Love, Nanhai G. Chen, Richard J. Aguilar, Aladar A. Szalay, Yuman Fong

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

Although early stage cholangiocarcinoma (CC) can be cured by surgical extirpation, the options for treatment of advanced stage CC are very few and suboptimal. Oncolytic virotherapy using replication-competent vaccinia virus (VACV) is a promising new strategy to treat human cancers. The ability of oncolytic VACV GLV-1h68 to infect, replicate in, and lyse three human CC cell lines was assayed in vitro and in subcutaneous flank xenografts in athymic nude mice. In this study, we have demonstrated that GLV-1h68 effectively infects and lyses three CC cell lines (KMC-1, KMBC, and KMCH-1) in vitro. Expression of the viral marker gene ruc-gfp facilitated real-time monitoring of infection and replication. Furthermore in athymic nude mice, a single dose of GLV-1h68 significantly suppressed tumor growth. The treatment was well tolerated in all animals. Recombinant VACV GLV-1h68 has significant oncolytic ability against CC both in vitro and in vivo. GLV-1h68 has the potential to be used clinically as a therapeutic agent against CC.

Original languageEnglish (US)
Pages (from-to)591-596
Number of pages6
JournalCancer gene therapy
Volume22
Issue number12
DOIs
StatePublished - 2015

Bibliographical note

Funding Information:
Technical services provided by the Research Animal Resource Center (RARC) and the Small–Animal Imaging Core Facilities at Memorial Sloan Kettering Cancer Center are greatly acknowledged. We would like to thank Valerie Longo at the imaging center for her valuable assistance. This study was supported in part by grants IMG0402501 from the Susan G. Komen Foundation and grant 032047 from the Flight Attendant Medical Research Institute (Prof Yuman Fong).

Fingerprint

Dive into the research topics of 'Recombinant vaccinia virus GLV-1h68 is a promising oncolytic vector in the treatment of cholangiocarcinoma'. Together they form a unique fingerprint.

Cite this